Etaracizumab

{
  "id": "MLC-T-ONC-003010",
  "term": "Etaracizumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of some types of cancer and other conditions. Etaracizumab binds to a protein on the surface of blood vessels and may prevent the growth of new blood vessels that tumors need to grow. It may also prevent the spread of cancer. It is a type of antiangiogenesis agent, a type of metastasis inhibitor, and a type of monoclonal antibody. Also called Abegrin, humanized monoclonal antibody MEDI-522, and MEDI-522.",
    "A humanized monoclonal IgG1 antibody directed against the vitronectin receptor alpha v beta 3 integrin. Etaracizumab blocks the binding of ligands, such as vitronectin, to alpha v beta 3 integrin, resulting in inhibition of angiogenesis and metastasis. Alpha v beta 3 integrin is a cell adhesion and signaling receptor that is expressed on the surface of tumor vessel endothelial cells, some tumor cells, and a number of other cell types."
  ],
  "synonyms": [
    "Abegrin",
    "humanized monoclonal antibody MEDI-522",
    "MEDI-522",
    "monoclonal antibody anti-alpha V beta 3 integrin MEDI-522"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/etaracizumab/"
}